ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1902

A Pattern of Higher Serum Levels of IL-10 and MMP-3, Along with Lower IL-6R, Identify RA Patients with Interstitial Lung Disease

Jon T. Giles1, Cheilonda Johnson2, Elana J. Bernstein3, Erika Darrah4, Felipe Andrade5 and Sonye K. Danoff6, 1Division of Rheumatology, Columbia University, College of Physicians and Surgeons, New York, NY, 2Medicine/Pulmonology, Johns Hopkins University School of Medicine, Baltimore, MD, 3Rheumatology, Columbia University, New York, NY, 4Department of Medicine/Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, MD, 5Medicine/Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 6Medicine, Johns Hopkins University School of Medicine, Baltimore, MD

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Biomarkers, Comorbidity, pathogenesis, pulmonary fibrosis and rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Rheumatoid Arthritis – Clinical Aspects III: Obesity and Other Comorbidities

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: The pathogenesis and prediction of RA-associated interstitial lung disease (ILD), an extra-articular manifestation with high morbidity and mortality, is poorly understood.  We explored the associations of serum levels of inflammatory mediators with radiographic ILD in RA.

Methods: RA patients participating in a study of subclinical cardiovascular disease underwent computed tomography (CT) of the chest with interpretation by a pulmonary radiologist for CT-ILD features.  A panel of 28 cytokines, chemokines, proteases, and other immune mediators was measured from serum using various optimized methods at the time of CT scanning.  Generalized linear models were constructed to model the serum biomarkers associated with CT-ILD.  A weighted biomarker score was constructed for each patient based on the biomarker level and its MV regression coefficient and modeled on CT-ILD, adjusting for pertinent confounders.

Results: A total of 156 RA patients [60% female, mean age 59 years, median RA duration=8 years, 76% seropositive for RF or anti-CCP, median DAS28=3.6] had both CT scanning and serum biomarkers measured.  Any CT-ILD was found in 47 (30%) with a pattern of ground glass opacification (GGO) in 18 (44% of those with ILD) and reticulation, traction bronchiectasis, or honeycombing (R/TB/HC) in 23 (56% of those with ILD).  In multivariable (MV) modeling, serum IL-10 and MMP-3 were significantly positively associated with any CT-ILD, while IL-6R was significantly inversely associated, even after adjusting for relevant confounders (listed in Fig).  The association of the weighted biomarker score based on these 3 factors with ILD was not linear, as there was a markedly stronger association among patients with a score above the median (adjOR=3.99; p=0.003), translating to an adjusted prevalence of ILD of 40% for those with a higher biomarker score vs. only 14% among those with a lower score (Fig A).  The association of the biomarker score was stronger for predicting R/TB/HC than GGO (Fig B), and was only significant among those with a history of smoking (Fig C).  The area under the receiver operator curve (AUC-ROC) for predicting any CT-ILD with the biomarker score alone was 0.654 (95%CI 0.573-0.734) which increased to 0.834 with the additional covariates added to the model.  The AUC-ROC for the biomarker score alone for predicting CT-ILD among ever smokers was 0.726 (95%CI 0.632-0.819).  Interestingly, those with a higher biomarker score did not differ from those with a lower score on demographics or RA disease activity, severity, or treatment characteristics.

Conclusion: Both IL-10 and MMP-3 have been implicated in lung fibrosis in non-RA diseases.  These findings suggest further evaluation of IL-10, MMP-3, and IL-6R levels are merited to determine if these biomarkers have utility in predicting ILD in some patients with RA, particularly among those with a history of smoking.

 


Disclosure: J. T. Giles, None; C. Johnson, None; E. J. Bernstein, None; E. Darrah, None; F. Andrade, None; S. K. Danoff, None.

To cite this abstract in AMA style:

Giles JT, Johnson C, Bernstein EJ, Darrah E, Andrade F, Danoff SK. A Pattern of Higher Serum Levels of IL-10 and MMP-3, Along with Lower IL-6R, Identify RA Patients with Interstitial Lung Disease [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/a-pattern-of-higher-serum-levels-of-il-10-and-mmp-3-along-with-lower-il-6r-identify-ra-patients-with-interstitial-lung-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-pattern-of-higher-serum-levels-of-il-10-and-mmp-3-along-with-lower-il-6r-identify-ra-patients-with-interstitial-lung-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology